However, combination therapy with PD-1/PD-L1 inhibitor 2 and TOE significantly increased the proportion of CD8+ T cells in the tumor microenvironment, while the proportion of CD4+ T cells remained unchanged (Figures 2E, G, H). This evidence concerns the gene CD4 and neoplasm.